AU667611B2 - Syrup containing N-acetyl-cysteine - Google Patents

Syrup containing N-acetyl-cysteine

Info

Publication number
AU667611B2
AU667611B2 AU56266/94A AU5626694A AU667611B2 AU 667611 B2 AU667611 B2 AU 667611B2 AU 56266/94 A AU56266/94 A AU 56266/94A AU 5626694 A AU5626694 A AU 5626694A AU 667611 B2 AU667611 B2 AU 667611B2
Authority
AU
Australia
Prior art keywords
nac
syrup
sodium
solution
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU56266/94A
Other versions
AU5626694A (en
Inventor
Daniele Bonadeo
Annibale Gazzaniga
Alessandro Saudino
Federico Stroppolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon SpA
Original Assignee
Zambon Group SpA
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group SpA, Zambon SpA filed Critical Zambon Group SpA
Publication of AU5626694A publication Critical patent/AU5626694A/en
Application granted granted Critical
Publication of AU667611B2 publication Critical patent/AU667611B2/en
Assigned to ZAMBON S.P.A. reassignment ZAMBON S.P.A. Alteration of Name(s) in Register under S187 Assignors: ZAMBON GROUP S.P.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Description

SYRUP CONTAINING N-ACETYL-CYSTEINE The present invention relates to a composition in the form of a syrup containing N-acetyl-cysteine as active ingredient .
N-acetyl-cysteine (hereinafter briefly referred to as NAC) is a compound endowed with several useful pharmacological properties, making it a widely used drug. •
In the treatment of cold diseases, NAC showed to be useful thanks TO its mucolytic properties.
One of the pharmaceutical forms largely used in the therapy of cold diseases is syrup, particularly suitable also for pediatric use.
NAC is available in several pharmaceutical forms, however the high reactivity of the molecule, the relative instability and the characteristic sulphureous smell and taste make extremely troublesome the achievement of liquid forms for oral use which are time-stable and with a good palatability.
The preparation of a syrup provides, practically in ail the cases, the use of a disaccharide (sucrose) or of a simple sugar as a sweetening and thickening agent of the aqueous solution of the drug. However, the interaction of NAC with sugars gives to the solution an unacceptable brown colouring and the titre of NAC decreases.
Thus, it is not possible to leave NAC in solution for a long time in the presence of sucrose.
Similarly, the reactions giving brown colour and causing bad smell take place also between NAC and the monosaccharides whose use is described in the French patent application No. 2631831 in the name of Calco Anstalt.
As far as we know, the only syrup formulation containing NAC on the market consists in a composition to be prepared at the moment of use by dissolution in water of a granulate. After preparation, the extemporaneous syrup must be used within 3 weeks.
We have now surprisingly found that it is possible to prepare a time-stable NAC syrup having a pleasant taste without using sugars.
Therefore, object of the present invention is a composition in the form of a syrup containing (each 100 ml) :
- N-acetyl-cysteine 2 -4.2 g/100 ml
- a sweetening agent 0.02-0.3 g/100 ml
- a thickening agent selected among: sodium carboxymethylcellulose and hydroxypropylmethylcellulose or mixtures thereof 0.1 -A g/100 mi and optionally:
- a flavouring agent 0.1 -0.4 g/100 ml - a preservative 0.05-0.5 g/100 ml and further
- water q.s. to 100 ml pH being settled within the interval 5-8.
The above solution results to be stable in a closed bottle under inert gas for at least 2 years under environmental conditions. When the bottle is opened, the solution shows to have a pleasant taste and to be free from bad smells; NAC maintains the initial titre and the open syrup results to be stable for at least 5 weeks.
For sweetening agent we mean a substance able to give a sweet taste to the solution but wich does not contain sugars. Specific examples of sweetening agents are saccharin, sodium saccharin and cyclamates or mixtures thereof.
The amount of sweetening agent will be the minimum amount sufficient to give a pleasant taste to the solution. The thickening agent is selected among sodium carboxymethylcellulose methylcellulose and hydroxypropylmethylcellulose or mixtures thereof. Surprisingly, these substances showed to be compatible with
NAC and to be able to give to the solution a thickness suitable for ς the usual palatability of a syrup.
To these three base components (NAC, sweetening agent and thickening agent) water can be added up to the selected volume, by optionally rectifying the resultant pH so that it is maintained within the interval from 5 to 8. Preferably, pH will be from 6.5 to 7. The syrup could also, but not necessarily, contain a flavouring agent in order to improve the palatability, especially for pediatric use.
Since the syrup is generally manufactured in absence of asepsis, phar acopoeiae require the compulsory presence of a preservative. The preservative is further required to assure the microbiological quality during the time of use by the patient.
In this case, preservatives selected among sodium benzoate, methyl • -hydroxybenzoate, propyl •.-hydroxybenzoate and mixtures thereof will be preferably used. With the double function of preservative and of metal chelating agent also sodium EDTA could be used in addition to or in partial substitution of the above preservatives.
The preparation of the syrup according to the present invention is carried out under inert gas by simple dissolution of the substances in the predetermined amount of water.
The resultant solution is shared into multidose bottles or in single-dose containers.
The packaging of multi-dose bottles could provide the contemporaneous supplying of a graduated measure for the correct dosage of the single doses for grown-up people (for example 10 ml) or for children - A -
( for example 5 ml ) .
In order to better illustrate the present invention the following examples are now given. ς
Example 1
10 liters of a syrup containing (each 100 ml):
NAC 2.1 g
Saccharin 0.04 g
Sodium carboxymethylcellulose 0.2 g Sodium benzoate 0.15 g
Sodium edetate 0.1 g
Raspberry flavour 0.25 g
Water q.s. to 100 ml were prepared by simple dissolution of the substances in purified and de-aerated water under nitrogen atmosphere.
The pH of the resultant solution was rectified to the correct value
6.5 by addition of sodium hydroxide.
The solution was shared at the rate of 150 ml/bottle.
The bottles were stored for 2 years at room temperature. After this period, the titre of NAC resulted to be higher than 95% of the initial one.
Such a titre resulted to be higher than 90% of the initial one also after 5 weeks from the opening of the bottle.
The syrup, also after 2 years of storage, showed to have a pleasant taste and smell and a good general palatability.
Example 2
10 1 of a syrup having the following composition (each 100 ml):
NAC 2.1 g
Sodium saccharin 0.04 g
Hydroxypropyl ethylcellulose 0.2 g Methyl 4-hydroxybenzoate 0.1 g Sodium edetate 0.1 g
Apricot flavour 0.1 g
Water q.s. to 100 ml were prepared by dispersion of hydroxypropylmethylcellulose in a part of boiling water which was cooled to room temperature. After hydration of hydroxypropylmethylcellulose, it was poured into a solution obtained by dissolving all the remaining substances in purified and de-aerated water, under nitrogen atmosphere.
The pH of the solution was rectified to pH 6.5 with sodium hydroxide.
The solution was shared into single-dose sachets of 10 ml each containing about 200 mg of NAC. Example 3
10 1 of a syrup having the following composition (each 100 ml):
NAC 2.1 g
Sodium saccharin 0.04 g
Hydroxypropylmethylcellulose 0.2 g Sodium edetate 0.1 g
Apricot flavour 0.1 g
Water q.s. to 100 ml were prepared by dispersion of hydroxypropylmethylcellulose in a part of boiling water which was cooled to room temperature. After hydration of hydroxypropylmethylcellulose, it was poured into a solution obtained by dissolving all the remaining substances in purified and de-aerated water, under nitrogen atmosphere.
The pH of the solution was rectified to pH 6.5 with sodium hydroxide. The solution was shared into single-dose glass vials of 10 ml with rubber stopper each containing about 200 mg of NAC.
Example 4 By working as described in Example 1, 10 1 of syrup having the following composition (each 100 ml) were prepared: NAC 4.2 g
Sodium saccharin 0.08 g
Sodium carboxymethylcellulose 0.20 g Sodium benzoate 0.15 g
Sodium edetate 0.10 g
Raspberry flavour 0.4 g
Water q.s. to 100 ml
The pH of the solution was rectified to pH 6.5 with sodium hydroxide.
The solution was shared into bottles at the rate of 150 ml each bottle.
Example 5 By working as described in Example 2, 10 1 of syrup having the following composition (each 100 ml) were prepared: NAC 2.10 g
Saccharin 0.04 g
Hydroxypropylmethylcellulose 0.40 g Methyl 4-hydroxybenzoate 0.10 g Banana flavour 0.4 g Water q.s. to 100 ml
The pH of the solution was rectified to pH 7 with sodium hydroxide. The solution was shared into bottles at the rate of 450 ml each bottle.

Claims (1)

  1. Claims
    1) A composition in the form of a syrup containing (each 100 mi):
    - N-acetyl-cysteine 2 -4.2 g/100 mi
    5 - a sweetening agent 0.02-0.3 g/100 mi
    - a thickening agent selected among: sodium carboxymethylcellulose and hydroxypropylmethylcellulose or mixtures thereof 0.1 -4 g/100 mi
    10 and optionally:
    - a flavouring agent 0.1 -0.4 g/100 mi
    - a preservative 0.05-0.5 g/100 ml and further
    - water q.s. to 100 ml
    •5 pH being settled within the interval 5-8.
    2) A composition according to claim 1 wherein the sweetening agent is selected among saccharin, sodium saccharin, cyclamates or mixtures thereof.
    3) A composition according to claim 1 wherein the preservative is 0 selected among sodium edetate, sodium benzoate, methyl
    4-hydroxybenzoate, propyl 4-hydroxybenzoate and mixtures thereof.
    4) A composition according to claim 1 wherein the pH is between 6.5 and 7.
    5
    0
AU56266/94A 1992-12-02 1993-11-23 Syrup containing N-acetyl-cysteine Expired AU667611B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI92002758 1992-12-02
ITMI922758A IT1256616B (en) 1992-12-02 1992-12-02 SYRUP CONTAINING N-ACETYL-CISTEIN
PCT/EP1993/003280 WO1994012168A1 (en) 1992-12-02 1993-11-23 Syrup containing n-acetyl-cysteine

Publications (2)

Publication Number Publication Date
AU5626694A AU5626694A (en) 1994-06-22
AU667611B2 true AU667611B2 (en) 1996-03-28

Family

ID=11364395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56266/94A Expired AU667611B2 (en) 1992-12-02 1993-11-23 Syrup containing N-acetyl-cysteine

Country Status (23)

Country Link
JP (1) JPH08503703A (en)
AT (1) AT407113B (en)
AU (1) AU667611B2 (en)
BE (1) BE1006799A3 (en)
CA (1) CA2150462C (en)
CH (1) CH685371A5 (en)
CZ (1) CZ282550B6 (en)
DE (2) DE4396086T1 (en)
DK (1) DK176247B1 (en)
ES (1) ES2070806B1 (en)
FR (1) FR2698545B1 (en)
GB (1) GB2288977B (en)
HU (2) HU221484B (en)
IT (1) IT1256616B (en)
LU (1) LU88618A1 (en)
MD (1) MD1714G2 (en)
NL (1) NL194957C (en)
NO (1) NO314018B1 (en)
NZ (1) NZ258544A (en)
RU (1) RU2108777C1 (en)
SE (1) SE520834C2 (en)
UA (1) UA27142C2 (en)
WO (1) WO1994012168A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT766557E (en) * 1994-06-23 2002-05-31 Procter & Gamble APPLICATION COMPOSITIONS TOPIC COMPREHENDING N-ACETYL-CYSTEIN
JP4501023B2 (en) * 2002-11-14 2010-07-14 小林製薬株式会社 Composition with reduced bitterness and odor of cysteines
JP4501024B2 (en) * 2002-11-14 2010-07-14 小林製薬株式会社 Composition with reduced bitterness and odor of cysteines
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
CN102233139B (en) * 2010-04-21 2012-09-05 重庆健能医药开发有限公司 Acetylcysteine effervescent tablet and preparation method and application thereof
RU2611411C1 (en) * 2016-01-11 2017-02-21 Общество с ограниченной ответственностью "Трейдсервис" Dispersible in water acetylcysteine tablet and method of manufacturing thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192789A (en) * 1986-07-24 1988-01-27 Inpharzam Int Sa Acetylcysteine compositions
FR2631831A1 (en) * 1988-05-31 1989-12-01 Calco Anstalt Syrups based on xylitol, ribitol or arabitol
EP0481294A1 (en) * 1990-10-19 1992-04-22 Spirig Ag Pharmazeutische Präparate Solid fast-dissolving pharmaceutical preparation containing S-(carboxymethyl)-L-cysteine and/or N-acetyl-cysteine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB905197A (en) * 1960-01-01 1962-09-05 Lab Francais Chimiotherapie Anti-viral compositions comprising 1-phenyl-2-amino-propane-1,3-diol derivatives
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
BE901885A (en) * 1985-03-06 1985-07-01 Bruschettini Srl Stable ophthalmic soln. contg. N-acetyl-cysteine - prepd. in nitrogen satd. aq. buffer free of metal ions
CH667590A5 (en) * 1986-07-24 1988-10-31 Inpharzam Int Sa WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. .
US4861797A (en) * 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
CH674940A5 (en) * 1988-05-05 1990-08-15 Ibsa Inst Biochimique Sa
ATE87476T1 (en) * 1988-11-10 1993-04-15 Ciba Geigy Ag LIQUID ORAL FORMULATION.
IT1231012B (en) * 1989-07-27 1991-11-08 Zambon Spa PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING NAC.
IT1248998B (en) * 1990-06-26 1995-02-11 Iscofar Sas COMPOSITION OF RUBBER TO BE CHEWED FOR THE PREVENTION AND TREATMENT OF DENTAL PLATE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192789A (en) * 1986-07-24 1988-01-27 Inpharzam Int Sa Acetylcysteine compositions
FR2631831A1 (en) * 1988-05-31 1989-12-01 Calco Anstalt Syrups based on xylitol, ribitol or arabitol
EP0481294A1 (en) * 1990-10-19 1992-04-22 Spirig Ag Pharmazeutische Präparate Solid fast-dissolving pharmaceutical preparation containing S-(carboxymethyl)-L-cysteine and/or N-acetyl-cysteine

Also Published As

Publication number Publication date
BE1006799A3 (en) 1994-12-13
CA2150462A1 (en) 1994-06-09
ES2070806A1 (en) 1995-06-01
SE9502001D0 (en) 1995-06-01
HUT72668A (en) 1996-05-28
HU211912A9 (en) 1996-01-29
MD1714G2 (en) 2002-03-31
DK61495A (en) 1995-05-31
CZ136795A3 (en) 1995-11-15
JPH08503703A (en) 1996-04-23
CZ282550B6 (en) 1997-08-13
CA2150462C (en) 2005-04-19
NO314018B1 (en) 2003-01-20
HU9501586D0 (en) 1995-08-28
NL9320052A (en) 1995-08-01
ES2070806B1 (en) 1996-01-01
GB2288977B (en) 1996-09-04
LU88618A1 (en) 1995-12-01
HU221484B (en) 2002-10-28
DK176247B1 (en) 2007-04-16
UA27142C2 (en) 2000-02-28
SE9502001L (en) 1995-07-21
ATA906093A (en) 2000-05-15
DE4396086B3 (en) 2013-02-28
SE520834C2 (en) 2003-09-02
ITMI922758A0 (en) 1992-12-02
NZ258544A (en) 1996-11-26
WO1994012168A1 (en) 1994-06-09
AT407113B (en) 2000-12-27
AU5626694A (en) 1994-06-22
NO952183D0 (en) 1995-06-01
GB9509822D0 (en) 1995-07-19
DE4396086T1 (en) 1995-12-07
GB2288977A (en) 1995-11-08
NL194957C (en) 2003-09-02
FR2698545A1 (en) 1994-06-03
FR2698545B1 (en) 1995-08-04
IT1256616B (en) 1995-12-12
CH685371A5 (en) 1995-06-30
MD1714F2 (en) 2001-08-31
NO952183L (en) 1995-06-01
RU2108777C1 (en) 1998-04-20
ITMI922758A1 (en) 1994-06-02
NL194957B (en) 2003-05-01

Similar Documents

Publication Publication Date Title
EP0431663B1 (en) Stabilized solutions of psychotropic agents
CA2121435C (en) Aqueous pharmaceutical suspension and process for preparation thereof
CZ114093A3 (en) Sulfate of 3-£2-(dimethylamino)ethyl-n-methyl-1h-indole-5-methane sulfonamide, and pharmaceutical preparations containing thereof
ES2210121T3 (en) STABLE PHARMACEUTICAL PREPARATION, WHICH CAN BE USED BY NASAL, ORAL OR SUBLINGUAL VIA CONTAINING DESMOPRESIN.
AU667611B2 (en) Syrup containing N-acetyl-cysteine
US5807894A (en) Syrup containing N-acetyl-cysteine
PT1747781E (en) Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients
US20230301945A1 (en) Stable pharmaceutical compositions of hydroxyurea
JPS5914447B2 (en) pH and Color Stabilized Aqueous Antibiotic Compositions for Parenteral Administration
KR20050034619A (en) New dry and aqueous epinastine-syrup-formulation
KR100254107B1 (en) Stable liquid preparation of complex vitamin for internal use
US3109773A (en) Bronchodilator expectorant composition containing theophylline and a guaiacol
CZ243898A3 (en) Aqueous formulation of bambuterol and application thereof
JPH08337522A (en) Aqueous liquid preparation of ambroxole hydrochloride
CA2120751C (en) Trimethoprim oral liquid
USRE29359E (en) Bronchodilator expectorant composition containing theophylline and a guaiacol
US20030104017A1 (en) Epinastine formulation for oral administration
JP2000204036A (en) Glutamic salt-containing liquid preparation
KR100718211B1 (en) Tixocortol Pivalate Suspension, Mouth-Wash Based Thereon and Packaging Containing Same
JPH085784B2 (en) Syrup
JPH11139970A (en) Oral solution
NL193607C (en) Pharmaceutical preparation containing N-acetylcysteine.
JPH0819000B2 (en) Syrup
MXPA00005129A (en) Liquid and stable antihistaminic - anti-congestive pharmaceutical compositions
ES2684594A1 (en) Aqueous solution of ranitidine free of ethanol (Machine-translation by Google Translate, not legally binding)